Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Molecular characteristics of hepatocellular carcinomas (HCC) from different age groups

Date

08 Oct 2016

Session

Gastrointestinal tumours, non-colorectal

Presenters

Celina Ang

Citation

Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371

Authors

C. Ang1, A. Shields2, J. Xiu3, Z. Gatalica4, S. Reddy3, M. Salem5, C.J. Farhangfar6, J. Hwang6, I. Astsaturov7, J. Marshall5

Author affiliations

  • 1 Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 10029 - New York/US
  • 2 Oncology, Karmanos Cancer Institute, Detroit/US
  • 3 Medical Affairs, Caris Life Sciences, 85040 - Phoenix/US
  • 4 Pathology, Caris Life Sciences, 85224 - Phoenix/US
  • 5 Division Of Hematology And Oncology, Lombardi Cancer Center Georgetown University, 20007 - Washington/US
  • 6 Tissue Procurement & Translational Research Levine Cancer Institute, Levine Cancer Institute, Charlotte/US
  • 7 Oncology, Fox Chase Cancer Center, Philadelphia/US
More

Resources

Background

HCC patients (pts) from the Western hemisphere are usually diagnosed in their 50s and 60s, whereas HCCs in young adults (YA, 18-39 years) and the elderly (E, >75 years) are less common. Worldwide, HCCs diagnosed at extremes of the age spectrum are associated with distinct geography and etiologies. Multiplatform profiling data were used to compare molecular characteristics of HCCs of different age groups.

Methods

Gene sequencing, amplification and protein expression data on 421 HCC specimens were reviewed and stratified into YA, E and intermediate age (IA, 40-74 years) subgroups. Only pathogenic or presumed pathogenic (P/PP) mutations were analyzed. The Chi-square test was used for statistical comparisons. Etiologies are being collected.

Results

There were 39 YA, 336 IA and 46 E pts. Female prevalence was higher in YAs (54%) vs IA (23%, p  0.05). MRP1 expression decreased in YAs (60%) vs IA (86%, p = 0.04) and E pts (95%, p = 0.02). MGMT was higher in IA than YA (71% vs. 49%, p = 0.007) and SPARC higher in E than YA (13% vs.0, p = 0.005). PDGFR and PD-L1 were expressed in IA (14% and 10%) and E pts (29% and 17%) but not YAs. Of 47 genes analyzed, TP53 was the most frequent alteration in YAs (19%) while CTNNB1 was the most frequent in E (33%) and IA (30%) and only 9.5% in YA . PIK3CA, PTEN, and PTPN11 mutations were more prevalent in E (13.3%, 7.1% and 6.7%, respectively) vs IA pts (1.4%, 0.7% and 0%, all p 

Conclusions

HCCs from YAs were associated with female sex, decreased drug resistance protein and AR expression. YAs may be more sensitive to alkylating agents whereas E pts may be more sensitive to PIK3CA/Akt/mTOR or MAPK pathway inhibitors. Our results provide important knowledge to prospective studies among a network of cancer centers that will also incorporate etiological factors and molecular features into investigations for HCC therapies.

Clinical trial identification

Legal entity responsible for the study

Celina Ang

Funding

N/A

Disclosure

J. Xiu, Z. Gatalica, S. Reddy: Employee of Caris Life Sciences. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings